Enliven Therapeutics Statistics
Total Valuation
ELVN has a market cap or net worth of $785.60 million. The enterprise value is $502.60 million.
Important Dates
The last earnings date was Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ELVN has 49.07 million shares outstanding. The number of shares has increased by 18.45% in one year.
| Current Share Class | 49.07M |
| Shares Outstanding | 49.07M |
| Shares Change (YoY) | +18.45% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | 5.37% |
| Owned by Institutions (%) | 63.02% |
| Float | 26.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.72 |
| P/TBV Ratio | 2.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.06, with a Debt / Equity ratio of 0.00.
| Current Ratio | 21.06 |
| Quick Ratio | 20.72 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -31.30% and return on invested capital (ROIC) is -22.71%.
| Return on Equity (ROE) | -31.30% |
| Return on Assets (ROA) | -21.36% |
| Return on Invested Capital (ROIC) | -22.71% |
| Return on Capital Employed (ROCE) | -38.21% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.53M |
| Employee Count | 62 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ELVN has paid $232,000 in taxes.
| Income Tax | 232,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.12% in the last 52 weeks. The beta is 1.10, so ELVN's price volatility has been higher than the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | -33.12% |
| 50-Day Moving Average | 18.53 |
| 200-Day Moving Average | 22.43 |
| Relative Strength Index (RSI) | 37.79 |
| Average Volume (20 Days) | 338,601 |
Short Selling Information
The latest short interest is 6.54 million, so 13.32% of the outstanding shares have been sold short.
| Short Interest | 6.54M |
| Short Previous Month | 6.96M |
| Short % of Shares Out | 13.32% |
| Short % of Float | 24.60% |
| Short Ratio (days to cover) | 19.97 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -110.26M |
| Pretax Income | -79.60M |
| Net Income | -94.83M |
| EBITDA | -109.95M |
| EBIT | -110.26M |
| Earnings Per Share (EPS) | -$1.93 |
Full Income StatementBalance Sheet
The company has $289.56 million in cash and $667,000 in debt, giving a net cash position of $288.89 million or $5.89 per share.
| Cash & Cash Equivalents | 289.56M |
| Total Debt | 667,000 |
| Net Cash | 288.89M |
| Net Cash Per Share | $5.89 |
| Equity (Book Value) | 288.30M |
| Book Value Per Share | 5.88 |
| Working Capital | 280.35M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$73.96 million and capital expenditures -$44,000, giving a free cash flow of -$74.00 million.
| Operating Cash Flow | -73.96M |
| Capital Expenditures | -44,000 |
| Free Cash Flow | -74.00M |
| FCF Per Share | -$1.51 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |